Fortress Biotech, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $63.3M | $57.7M | $84.5M | $75.7M | $68.8M | $45.6M | $36.6M | $26.9M |
| Cost of Revenue | $20.9M | $20.9M | $22.9M | $30.8M | $32.1M | $14.6M | $10.5M | $6.1M |
| Gross Profit | $42.3M | $36.8M | $61.6M | $45.0M | $36.7M | $31.0M | $26.1M | $20.8M |
| Gross Margin | 66.9% | 63.8% | 72.9% | 59.4% | 53.4% | 68.0% | 71.2% | 77.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | $106.1M | $134.9M | $128.9M | $64.1M | $81.3M | $87.4M |
| SG&A Expense | $96.4M | $87.7M | $91.0M | $113.7M | $86.8M | $61.2M | $55.6M | $53.4M |
| Operating Income | $-70.2M | $-110.4M | $-142.3M | $-203.6M | $-188.5M | $-94.3M | $-110.8M | $-120.0M |
| Operating Margin | -111.0% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% |
| Interest Expense | $10.1M | $13.5M | $15.3M | $12.5M | $15.3M | $15.3M | $11.8M | — |
| Pretax Income | $-33.5M | $-120.5M | $-153.6M | $-213.5M | $-164.4M | $-102.8M | $-101.7M | $-130.8M |
| Income Tax Expense | $-620.0K | $312.0K | $521.0K | $449.0K | $473.0K | $500.0K | $0 | $0 |
| Net Income | $6.8M | $-46.0M | $-60.6M | $-86.6M | $-64.7M | $-46.5M | $-40.0M | $-84.1M |
| Net Margin | 10.8% | -79.8% | -71.7% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% |
| EPS (Basic) | $-0.07 | $-2.69 | $-2.82 | $-5.32 | $-0.26 | $-0.22 | $-0.24 | $-0.65 |
| EPS (Diluted) | $-0.07 | $-2.69 | $-2.82 | $-5.32 | $-0.26 | $-0.22 | $-0.24 | $-0.65 |
| Shares Outstanding (Basic) | 27.9M | 20.8M | 24.3M | 17.8M | 245.1M | 284.6M | 222.1M | 173.5M |
| Shares Outstanding (Diluted) | 27.9M | 20.8M | 24.3M | 17.8M | 245.1M | 284.6M | 222.1M | 173.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |